LAMEA Vulvovaginal Candidiasis Treatment Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Oral, Intravenous and Topical), By Drug Class, By Country and Growth Forecast, 2022 - 2028

The Latin America, Middle East and Africa Vulvovaginal Candidiasis Treatment Market would witness market growth of 7.9% CAGR during the forecast period (2022-2028).

Self-treatment of VVC by using available OTC vaginal antifungals is considered an efficient way to treat patients with infrequent and uncomplicated episodes of vulvovaginal candidiasis. It is crucial to differentiate between vulvovaginal candidiasis and other causes of vaginal infections, such as bacterial vaginosis, to get appropriate treatment on time. Pharmacists may suggest using vaginal screening kits to confirm or identify the occurrence of vulvovaginal candidiasis. These kits are equally accurate as the standard diagnostics testing for vulvovaginal candidiasis.

In addition, the patients are suggested to undergo a proper medical diagnosis in case of the first episode of VVC when the woman is pregnant. Nearly all OTC vaginal antifungal products are approved for the treatment of vulvovaginal candidiasis. Single-dose oral treatment or short-course topical formulations are considered effective in treating most uncomplicated cases.

Vulvovaginal candidiasis is a common yeast infection usually caused by Candida albicans. However, various non Albicans species are also linked with the occurrence of VVC. These non-albicans species include C. tropicalis, C. parapsilosis, and C. glabrata. One of the symptoms of vulvovaginal candidiasis is abnormal white floccular discharge. The vulvovaginal candidiasis could be diagnosed by undergoing a physical examination combining the presence of blastospores or hyphae on KOH preparation.

The middle east region offers great growth potential to marketers in the pharmaceutical industry. This is due to the government's support for the growth of healthcare services, favorable economic factors, and the rollout of compulsive health insurance schemes. Furthermore, the government in the region is widely investing in the digital transformation of the healthcare sector. Also, due to the outspread of the pandemic, the Middle East's technology industry is growing rapidly. The outspread of the pandemic is opening doors for the pharmaceutical and telehealth sector. In addition, various women's health awareness programs have been launched by the regional government, which would further support the market expansion of vulvovaginal candidiasis treatment.

The Brazil market dominated the LAMEA Vulvovaginal Candidiasis Treatment Market by Country in 2021; thereby, achieving a market value of $24.4 million by 2028. The Argentina market is showcasing a CAGR of 8.4% during (2022 - 2028). Additionally, The UAE market would register a CAGR of 7.6% during (2022 - 2028).

Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Oral, Intravenous and Topical. Based on Drug Class, the market is segmented into Fluconazole, Clotrimazole, Terconazole, Terbinafine, Nystatin, Ketoconazole and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: The Global Vulvovaginal Candidiasis Treatment Market is Predict to reach $1.3 Billion by 2028, at a CAGR of 4.6%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

By Route of Administration

• Oral
• Intravenous
• Topical

By Drug Class

• Fluconazole
• Clotrimazole
• Terconazole
• Terbinafine
• Nystatin
• Ketoconazole
• Others

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Bayer AG
• Bristol Myers Squibb Company
• Pfizer, Inc.
• Astellas Pharma, Inc.
• Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC)
• Basilea Pharmaceutica Ltd.
• Scynexis, Inc.
• Grupo Ferrer Internacional S.A.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Vulvovaginal Candidiasis Treatment Market, by Distribution Channel
1.4.2 LAMEA Vulvovaginal Candidiasis Treatment Market, by Route of Administration
1.4.3 LAMEA Vulvovaginal Candidiasis Treatment Market, by Drug Class
1.4.4 LAMEA Vulvovaginal Candidiasis Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. LAMEA Vulvovaginal Candidiasis Treatment Market by Distribution Channel
3.1 LAMEA Retail Pharmacy Market by Country
3.2 LAMEA Hospital Pharmacy Market by Country
3.3 LAMEA Online Pharmacy Market by Country

Chapter 4. LAMEA Vulvovaginal Candidiasis Treatment Market by Route of Administration
4.1 LAMEA Oral Market by Country
4.2 LAMEA Intravenous Market by Country
4.3 LAMEA Topical Market by Country

Chapter 5. LAMEA Vulvovaginal Candidiasis Treatment Market by Drug Class
5.1 LAMEA Fluconazole Market by Country
5.2 LAMEA Clotrimazole Market by Country
5.3 LAMEA Terconazole Market by Country
5.4 LAMEA Terbinafine Market by Country
5.5 LAMEA Nystatin Market by Country
5.6 LAMEA Ketoconazole Market by Country
5.7 LAMEA Others Market by Country

Chapter 6. LAMEA Vulvovaginal Candidiasis Treatment Market by Country
6.1 Brazil Vulvovaginal Candidiasis Treatment Market
6.1.1 Brazil Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.1.2 Brazil Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.1.3 Brazil Vulvovaginal Candidiasis Treatment Market by Drug Class
6.2 Argentina Vulvovaginal Candidiasis Treatment Market
6.2.1 Argentina Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.2.2 Argentina Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.2.3 Argentina Vulvovaginal Candidiasis Treatment Market by Drug Class
6.3 UAE Vulvovaginal Candidiasis Treatment Market
6.3.1 UAE Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.3.2 UAE Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.3.3 UAE Vulvovaginal Candidiasis Treatment Market by Drug Class
6.4 Saudi Arabia Vulvovaginal Candidiasis Treatment Market
6.4.1 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.4.2 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.4.3 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Drug Class
6.5 South Africa Vulvovaginal Candidiasis Treatment Market
6.5.1 South Africa Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.5.2 South Africa Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.5.3 South Africa Vulvovaginal Candidiasis Treatment Market by Drug Class
6.6 Nigeria Vulvovaginal Candidiasis Treatment Market
6.6.1 Nigeria Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.6.2 Nigeria Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.6.3 Nigeria Vulvovaginal Candidiasis Treatment Market by Drug Class
6.7 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market
6.7.1 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Distribution Channel
6.7.2 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Route of Administration
6.7.3 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Drug Class

Chapter 7. Company Profiles
7.1 Bayer AG
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Pfizer, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional & Segmental Analysis
7.2.4 Research & Development Expense
7.3 Bristol Myers Squibb Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Astellas Pharma, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.5 Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management, LLC)
7.5.1 Company Overview
7.5.2 Recent strategies and developments:
7.5.2.1 Trials and Approvals:
7.6 Basilea Pharmaceutica Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.7 Scynexis, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Trials and Approvals:
7.8 Grupo Ferrer Internacional S.A.
7.8.1 Company Overview

TABLE 1 LAMEA Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 2 LAMEA Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 3 LAMEA Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 4 LAMEA Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 5 LAMEA Retail Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 6 LAMEA Retail Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 7 LAMEA Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 8 LAMEA Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 9 LAMEA Online Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 10 LAMEA Online Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 11 LAMEA Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 12 LAMEA Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 13 LAMEA Oral Market by Country, 2018 - 2021, USD Million
TABLE 14 LAMEA Oral Market by Country, 2022 - 2028, USD Million
TABLE 15 LAMEA Intravenous Market by Country, 2018 - 2021, USD Million
TABLE 16 LAMEA Intravenous Market by Country, 2022 - 2028, USD Million
TABLE 17 LAMEA Topical Market by Country, 2018 - 2021, USD Million
TABLE 18 LAMEA Topical Market by Country, 2022 - 2028, USD Million
TABLE 19 LAMEA Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 20 LAMEA Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 21 LAMEA Fluconazole Market by Country, 2018 - 2021, USD Million
TABLE 22 LAMEA Fluconazole Market by Country, 2022 - 2028, USD Million
TABLE 23 LAMEA Clotrimazole Market by Country, 2018 - 2021, USD Million
TABLE 24 LAMEA Clotrimazole Market by Country, 2022 - 2028, USD Million
TABLE 25 LAMEA Terconazole Market by Country, 2018 - 2021, USD Million
TABLE 26 LAMEA Terconazole Market by Country, 2022 - 2028, USD Million
TABLE 27 LAMEA Terbinafine Market by Country, 2018 - 2021, USD Million
TABLE 28 LAMEA Terbinafine Market by Country, 2022 - 2028, USD Million
TABLE 29 LAMEA Nystatin Market by Country, 2018 - 2021, USD Million
TABLE 30 LAMEA Nystatin Market by Country, 2022 - 2028, USD Million
TABLE 31 LAMEA Ketoconazole Market by Country, 2018 - 2021, USD Million
TABLE 32 LAMEA Ketoconazole Market by Country, 2022 - 2028, USD Million
TABLE 33 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 34 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 35 LAMEA Vulvovaginal Candidiasis Treatment Market by Country, 2018 - 2021, USD Million
TABLE 36 LAMEA Vulvovaginal Candidiasis Treatment Market by Country, 2022 - 2028, USD Million
TABLE 37 Brazil Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 38 Brazil Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 39 Brazil Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 40 Brazil Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 41 Brazil Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 Brazil Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 Brazil Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 44 Brazil Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 45 Argentina Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 46 Argentina Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 47 Argentina Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 48 Argentina Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 49 Argentina Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 50 Argentina Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 51 Argentina Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 52 Argentina Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 53 UAE Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 54 UAE Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 55 UAE Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 56 UAE Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 57 UAE Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 58 UAE Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 59 UAE Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 60 UAE Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 61 Saudi Arabia Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 62 Saudi Arabia Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 63 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 64 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 65 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 66 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 67 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 68 Saudi Arabia Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 69 South Africa Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 70 South Africa Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 71 South Africa Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 72 South Africa Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 73 South Africa Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 74 South Africa Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 75 South Africa Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 76 South Africa Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 77 Nigeria Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 78 Nigeria Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 79 Nigeria Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 80 Nigeria Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 81 Nigeria Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 82 Nigeria Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 83 Nigeria Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 84 Nigeria Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 85 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market, 2018 - 2021, USD Million
TABLE 86 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market, 2022 - 2028, USD Million
TABLE 87 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 88 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 89 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 90 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 91 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Drug Class, 2018 - 2021, USD Million
TABLE 92 Rest of LAMEA Vulvovaginal Candidiasis Treatment Market by Drug Class, 2022 - 2028, USD Million
TABLE 93 Key Information – Bayer AG
TABLE 94 Key Information – Pfizer, Inc.
TABLE 95 Key Information – Bristol Myers Squibb Company
TABLE 96 key information – Astellas Pharma, Inc.
TABLE 97 Key Information – Mycovia Pharmaceuticals, Inc.
TABLE 98 Key Information – Basilea Pharmaceutica Ltd.
TABLE 99 Key Information – Scynexis, Inc.
TABLE 100 Key Information – Grupo Ferrer Internacional S.A.

List of Figures
FIG 1 Methodology for the research